Literature DB >> 9581857

Assessment of left ventricular function using serum cardiac troponin I measurements following myocardial infarction.

F S Apple1, S W Sharkey, A Falahati, M Murakami, N Mitha, D Christensen.   

Abstract

The prognosis and extent of injury to the myocardium have previously been assessed by increased serum creatine kinase (CK) MB levels. We report findings from 39 consecutive, acute myocardial infarction (AMI) patients presenting 4.5 h (range, 0.7-12.1 h) after the onset of chest pain. We compared CK MB mass (upper reference limit, 5.0 ng/ml) and cardiac troponin I (cTnI; upper reference limit, 0.8 ng/ml) (Stratus II, Dade International) in serial serum specimens obtained over 36 h after chest pain from AMI patients; within 6 h after onset of chest pain. While the appearance of the kinetics of CK MB and cTnI were similar during the initial 24 h following the onset of chest pain, cTnI was increased significantly (p < 0.05) over CK MB after 9 to 12 h. Half-life determinations (mean+/-S.D.) in 22 of the 39 AMI patients demonstrated a significantly (p < 0.01) shorter half-life in non-Q-wave infarcts [t1/2 6.8 h (+/-5.6)] vs. Q-wave infarcts [t1/2 20.4 h (+/-10.7)]. Further serial time versus marker (mean+/-S.D.) results were significantly correlated (p < 0.001, r = 0.66). Sixteen of twenty patients assessed by echocardiography had an abnormal left ventricular ejection fraction (LVEF); mean 37.6 (S.D. 15.2)%, ranging from 15.4 to 67.6%. LVEF was significantly and inversely correlated to peak CK MB (r = .50, p = 0.03), as well as to peak cTnI (r = 0.46, p = 0.04). Based on these findings, cTnI shows excellent promise as a useful marker of infarct size, for the assessment of left ventricular function, and may potentially replace CK MB as the cardiac-specific marker for AMI detection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9581857     DOI: 10.1016/s0009-8981(97)00252-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  7 in total

1.  Role of biomarkers in assessment of early infarct size after successful p-PCI for STEMI.

Authors:  Gert Klug; Agnes Mayr; Johannes Mair; Michael Schocke; Michael Nocker; Thomas Trieb; Werner Jaschke; Otmar Pachinger; Bernhard Metzler
Journal:  Clin Res Cardiol       Date:  2011-01-04       Impact factor: 5.460

2.  [Hair cortisol as chronic stress parameter in patients with acute ST-segment elevation myocardial infarction].

Authors:  Helena Crom; Hans-Joachim Trappe
Journal:  Herz       Date:  2020-10-07       Impact factor: 1.443

Review 3.  The continuing evolution of cardiac troponin I biomarker analysis: from protein to proteoform.

Authors:  Daniel Soetkamp; Koen Raedschelders; Mitra Mastali; Kimia Sobhani; C Noel Bairey Merz; Jennifer Van Eyk
Journal:  Expert Rev Proteomics       Date:  2017-10-16       Impact factor: 3.940

4.  Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction.

Authors:  Aslan T Turer; Kenneth W Mahaffey; Dianne Gallup; W Douglas Weaver; Robert H Christenson; Nathan R Every; E Magnus Ohman
Journal:  Curr Control Trials Cardiovasc Med       Date:  2005-08-23

5.  Implications of troponin testing in clinical medicine.

Authors:  Britta U Goldmann; Robert H Christenson; Christian W Hamm; Thomas Meinertz; E Magnus Ohman
Journal:  Curr Control Trials Cardiovasc Med       Date:  2001

Review 6.  Challenges in high-sensitive troponin assay interpretation for intensive therapy.

Authors:  Humberto Andres Vaz; Raphael Boesche Guimaraes; Oscar Dutra
Journal:  Rev Bras Ter Intensiva       Date:  2019-02-28

Review 7.  Troponins in myocardial infarction and injury.

Authors:  Julia M Potter; Peter E Hickman; Louise Cullen
Journal:  Aust Prescr       Date:  2022-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.